Revolutionary genetic drug trial will herald 'new era' in the fight against cancer

 

Health Reporter

A “revolutionary” drug trial aimed at discovering personalised treatments for the UK’s biggest cancer killer will begin this summer, scientists have announced, in an advance which experts say opens up a “new era” in the fight against cancer.

In an unprecedented partnership between cancer researchers, the NHS and the pharmaceutical industry, scientists will exploit a new understanding of the genetic properties of cancer tumours to help them identify drugs to be “targeted” at patients with specific variants of lung cancer.

Click image above to enlarge graphic

Scientists at Cancer Research UK, who have spearheaded the “genetic revolution” in cancer treatment, will be granted special access to the drugs libraries of pharmaceutical giants AstraZeneca and Pfizer from July this year.

Initially, the trials will test the effectiveness of 14 different drugs against 21 different genetic abnormalities identified in the tumours of several hundred lung cancer patients, but it is hoped that drugs which work against the various genetic varieties of every type of cancer may one day be discovered in this way.

The past decade has seen a major shift in our understanding of cancer. New technologies have allowed scientists to undertake detailed genetic analysis of cancer tumours for the first time, revealing the molecular changes that take place when cells transform from a normal part of a healthy body into a cancer cell.

Scientists have been able to identify a wide range of specific abnormalities, and cancers that were previously thought of as one condition have now been revealed to have particular genetic variants in different patients – opening up the potential for much more targeted drug treatments, known as stratified medicine.

The new trials, which will seek new treatments for patients with advanced stage, incurable lung cancer, are among the first of their kind in the world.

Professor Peter Johnson, chief clinician at Cancer Research UK, said that they marked the beginning of “a very exciting time” in the fight against cancer.

“We’ve been talking for a long while now about how the genetic revolution was going to impact cancer care and we’re really starting to bring these things together now,” he said. “We’re very excited about the trial that is going to start, where a number of different cancer drugs targeting these very specific abnormalities will be tested out.”

The trial will look at potential treatments for patients with advanced lung cancer. Small groups of patients will be identified who are likely to benefit from a certain drug. Up to 12 molecules developed by AstraZeneca will be included and two from Pfizer, but it is hoped that other pharmaceutical companies will open up their drugs libraries to cancer trials in the coming years.

Dr Harpal Kumer, Cancer Research UK’s chief executive, said that the trials would “re-write the rulebook”.

“What we’re talking about here is giving a number of options to patients who otherwise would have exhausted their treatment options,” he said. “Importantly it shifts the emphasis of designing a trial around a single drug to designing a trial that selects from a range of drugs, for a specific patient.”

X-ray of a lung cancer sufferer (Kallista Images/Getty) X-ray of a lung cancer sufferer (Kallista Images/Getty)

Lung cancer is the biggest cancer killer in the UK for men and the second-biggest for women. There are 42,000 diagnoses every year, and 35,000 people die of the disease. Globally it kills 1.6 million people a year and while rates are declining in men, women have become more susceptible in recent decades because of changes in patterns of smoking.

Dr Kumar said survival rates for the disease had remained stubbornly low, making it a good candidate for these first clinical applications of scientists’ new genetic understanding of cancer.

Menelas Pangalos, executive vice president of innovative medicines and early development at AstraZeneca, said that it was “not beyond the realms of possibility”, that the advent of targeted cancer drugs could, within a decade, transform the prospects for patients with certain types of tumour, potentially lengthening survival times dramatically.

“These [drugs] are very exciting molecules produced by our scientists, and one of the challenges we have is how to get these targeted molecules to the right patients in a cost-effective and time-effective way. [Over the next decade] we could start to offer patients a sequence of therapies that could prolong their life and make this more of a chronic illness, rather than an illness that is fatal within months,” he said.

Professor Johnson said he expected that analysing the “molecular landscape” of cancer patients’ tumours from the moment they are diagnosed would become the norm, allowing doctors to prescribe treatments aimed at the specific genetic characteristics of their cancers.

Patients from 18 Cancer Research UK centres, attached to NHS hospitals, will take part in the initial trial, which has been hailed as “ground-breaking by the Health Secretary Jeremy Hunt.

“Cancer Research UK’s stratified medicine programme will see top scientists work with industry and the NHS to collaborate on innovative, life-saving research,” Mr Hunt said. “I look forward to the benefits this will bring for cancer patients and their families.”

News
Bill Gates, founder of Microsoft and co-chair of the Bill and Melinda Gates Foundation
businessUber, Snapchat and Facebook founders among those on the 2015 Forbes Billionaire List
News
news... and what your reaction to the creatures above says about you
News
Homer’s equation, in an episode in 1998, comes close to the truth, as revealed 14 years later
science
News
news
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Ashdown Group: Finance Manager - Covent Garden, central London - £45k - £55k

    £45000 - £55000 per annum + 30 days holiday: Ashdown Group: Finance Manager - ...

    Ashdown Group: Systems Administrator - Lancashire - £30,000

    £28000 - £30000 per annum: Ashdown Group: 3rd Line Support Engineer / Network ...

    Recruitment Genius: Graduate Web Developer

    £26000 - £33000 per annum: Recruitment Genius: A Web Developer is required to ...

    Ashdown Group: PeopleSoft Developer - London - £45k

    £45000 per annum: Ashdown Group: PeopleSoft Application Support & Development ...

    Day In a Page

    The difference between America and Israel? There isn’t one

    The difference between America and Israel? There isn’t one

    Netanyahu knows he can get away with anything in America, says Robert Fisk
    Families clubbing together to build their own affordable accommodation

    Do It Yourself approach to securing a new house

    Community land trusts marking a new trend for taking the initiative away from developers
    Head of WWF UK: We didn’t send Cameron to the Arctic to see green ideas freeze

    David Nussbaum: We didn’t send Cameron to the Arctic to see green ideas freeze

    The head of WWF UK remains sanguine despite the Government’s failure to live up to its pledges on the environment
    Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

    Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

    Set in a mythologised 5th-century Britain, ‘The Buried Giant’ is a strange beast
    With money, corruption and drugs, this monk fears Buddhism in Thailand is a ‘poisoned fruit’

    Money, corruption and drugs

    The monk who fears Buddhism in Thailand is a ‘poisoned fruit’
    America's first slavery museum established at Django Unchained plantation - 150 years after slavery outlawed

    150 years after it was outlawed...

    ... America's first slavery museum is established in Louisiana
    Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

    Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

    The first 'American Idol' winner on how she manages to remain her own woman – Jane Austen fascination and all
    Tony Oursler on exploring our uneasy relationship with technology with his new show

    You won't believe your eyes

    Tony Oursler's new show explores our uneasy relationship with technology. He's one of a growing number of artists with that preoccupation
    Ian Herbert: Peter Moores must go. He should never have been brought back to fail again

    Moores must go. He should never have been brought back to fail again

    The England coach leaves players to find solutions - which makes you wonder where he adds value, says Ian Herbert
    War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

    The battle for Mosul will unleash 'a million refugees'

    Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
    Yvette Cooper: We can't lose the election. There's too much on the line

    Yvette Cooper: We can't lose the election. There's too much on the line

    The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
    A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

    It's not easy being Green

    After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
    Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

    Gorillas nearly missed

    BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
    Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

    The Downton Abbey effect

    Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
    China's wild panda numbers have increased by 17% since 2003, new census reveals

    China's wild panda numbers on the up

    New census reveals 17% since 2003